AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.
You may also be interested in...
Yescarta continued its growth trajectory, the HIV franchise showed solid sales growth and the hepatitis C franchise stayed steady – plus Gilead could jump to the head of the line in NASH.
In addition to endometriosis, Orilissa (elagolix), developed by Neurocrine and licensed to Abbvie, is in Phase III for treating heavy bleeding associated with uterine fibroids.
Q1 earnings far outpaced expectations due to the successful launch for new hepatitis C drug Mavyret, but with the HCV market overall in decline those gains won't last and won't make up for the looming loss of Humira revenue.